Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.05.06.20093237: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The Fragility Index is only one method to provide insight into the value of a trial and has limitations. For example, the application to non-randomized trials is controversial as it lacks control of confounding variables. To …
SciScore for 10.1101/2020.05.06.20093237: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The Fragility Index is only one method to provide insight into the value of a trial and has limitations. For example, the application to non-randomized trials is controversial as it lacks control of confounding variables. To further understand the results of Gautret et al and its applicability to future research and practice, focus should be spent on epidemiological aspects (i.e. trial design to control for confounder, inclusion/exclusion criteria, and choice of outcome), such as the analysis published by Kim et al [13]. In conclusion, the trial results reported by Gautret et al are statistically robust relative to other trials, but ideally need a higher Fragility Index and further investigation before the proposed regimen can be considered a viable treatment for COVID-19. Further analyses of the trial should be through the lens of epidemiology and clinical significance. Given the statistically robust results reported by Gautret et al, despite the study’s inherent methodological and analytical flaws, hydroxychloroquine should be studied as a potential agent against COVID-19 in larger clinical trials.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04252664 Suspended A Trial of Remdesivir in Adults With Mild and Moderate COVID… NCT04257656 Terminated A Trial of Remdesivir in Adults With Severe COVID-19 Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
-
